Abstract：
OBJECTIVE: To evaluate the 3-year outcomes of VEGF inhibitors in the treatment of cystoid macular edema due to branch retinal vein occlusion (BRVO) in an international multicenter cohort of eyes.
METHODS: Multicenter, international, BRVO database study.
METHODS: Seven hundred forty-seven patients (760 eyes) undergoing intravitreal therapy for BRVO for 3 years in a multicenter international setting.
METHODS: Demographics, visual acuity (VA) in logarithm of the minimum angle of resolution letters, central subfield thickness (CST), treatments, number of injections, and visits data was collected using a validated web-based tool.
METHODS: Visual acuity gain at 3 years in logarithm of the minimum angle of resolution letters. Secondary outcome measures included anatomical results, treatment pattern, and percentage of completers. A subgroup analysis by study drug was conducted for clinical outcomes.
RESULTS: Mean adjusted VA change was +11 letters (95% confidence interval 9-13), mean adjusted change in CST was -176 μm (-193, -159). Median number of injections/visits was 16 of 24 at 3 years of follow-up. Most eyes received VEGF inhibitors exclusively (89%, n = 677) and as a monotherapy in 71% (n = 538). Few eyes were switched to steroids (11%, n = 83). Suspensions in treatment >180 days occurred in 26% of study eyes. Aflibercept showed greater CST reductions (-147 vs. -128 vs. -114 μm; P < 0.001) and significantly lower switching rates (14% vs. 38% vs. 33%; P < 0.001) compared with ranibizumab and bevacizumab, respectively.
CONCLUSIONS: This international study of 3-year BRVO outcomes after starting treatment with VEGF inhibitors found adequate visual and anatomical results in routine clinical care. Visual outcomes were similar among the different initiating VEGF inhibitors, although eyes starting with aflibercept had better anatomical outcomes and a lower switching rate.
BACKGROUND: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
METHODS: Multicenter, international, BRVO database study.
METHODS: Seven hundred forty-seven patients (760 eyes) undergoing intravitreal therapy for BRVO for 3 years in a multicenter international setting.
METHODS: Demographics, visual acuity (VA) in logarithm of the minimum angle of resolution letters, central subfield thickness (CST), treatments, number of injections, and visits data was collected using a validated web-based tool.
METHODS: Visual acuity gain at 3 years in logarithm of the minimum angle of resolution letters. Secondary outcome measures included anatomical results, treatment pattern, and percentage of completers. A subgroup analysis by study drug was conducted for clinical outcomes.
RESULTS: Mean adjusted VA change was +11 letters (95% confidence interval 9-13), mean adjusted change in CST was -176 μm (-193, -159). Median number of injections/visits was 16 of 24 at 3 years of follow-up. Most eyes received VEGF inhibitors exclusively (89%, n = 677) and as a monotherapy in 71% (n = 538). Few eyes were switched to steroids (11%, n = 83). Suspensions in treatment >180 days occurred in 26% of study eyes. Aflibercept showed greater CST reductions (-147 vs. -128 vs. -114 μm; P < 0.001) and significantly lower switching rates (14% vs. 38% vs. 33%; P < 0.001) compared with ranibizumab and bevacizumab, respectively.
CONCLUSIONS: This international study of 3-year BRVO outcomes after starting treatment with VEGF inhibitors found adequate visual and anatomical results in routine clinical care. Visual outcomes were similar among the different initiating VEGF inhibitors, although eyes starting with aflibercept had better anatomical outcomes and a lower switching rate.
BACKGROUND: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
摘要：
目的：评价国际多中心研究人群中血管内皮生长因子（VEGF）抑制剂治疗视网膜分支静脉阻塞（BRVO）所致黄斑囊样水肿（CME）的3年疗效。
方法：多中心，国际,BRVO数据库研究。
方法：在多中心国际环境中接受BRVO玻璃体内治疗3年的747名患者（760只眼）。
方法：人口统计，视敏度（VA）的最小分辨率角（logMAR）字母的对数，中心子场厚度（CST），治疗,使用经过验证的基于网络的工具收集注射次数和访视数据.
方法：在LogMAR字母中，3年视力（VA）增加。次要结果指标包括解剖结果，处理模式和完成者百分比。对临床结果进行了研究药物的亚组分析。
结果：平均校正VA变化为+11个字母（95％CI9,13），CST的平均调整变化为-176μm（-193，-159）。在随访3年时，注射/访问的中位数为16/24。大多数眼睛只接受VEGF抑制剂（89%，n=677）和单药治疗71%（n=538）。很少有眼睛转向类固醇(11%，n=83）。>180天的治疗暂停发生在26%的研究眼睛中。Aflibercept显示出更大的CST降低（-147vs-128vs-114μm；p<0.001）和显着更低的转换率（14％vs38％vs33％，p<0.001）与雷珠单抗和贝伐单抗相比，分别。
结论：这项关于开始使用VEGF抑制剂治疗后3年BRVO结局的国际研究在常规临床护理中发现了足够的视觉和解剖学结果。不同起始VEGF抑制剂的视觉结果相似，尽管从阿柏西普开始的眼睛具有更好的解剖学结果和更低的转换率。
方法：多中心，国际,BRVO数据库研究。
方法：在多中心国际环境中接受BRVO玻璃体内治疗3年的747名患者（760只眼）。
方法：人口统计，视敏度（VA）的最小分辨率角（logMAR）字母的对数，中心子场厚度（CST），治疗,使用经过验证的基于网络的工具收集注射次数和访视数据.
方法：在LogMAR字母中，3年视力（VA）增加。次要结果指标包括解剖结果，处理模式和完成者百分比。对临床结果进行了研究药物的亚组分析。
结果：平均校正VA变化为+11个字母（95％CI9,13），CST的平均调整变化为-176μm（-193，-159）。在随访3年时，注射/访问的中位数为16/24。大多数眼睛只接受VEGF抑制剂（89%，n=677）和单药治疗71%（n=538）。很少有眼睛转向类固醇(11%，n=83）。>180天的治疗暂停发生在26%的研究眼睛中。Aflibercept显示出更大的CST降低（-147vs-128vs-114μm；p<0.001）和显着更低的转换率（14％vs38％vs33％，p<0.001）与雷珠单抗和贝伐单抗相比，分别。
结论：这项关于开始使用VEGF抑制剂治疗后3年BRVO结局的国际研究在常规临床护理中发现了足够的视觉和解剖学结果。不同起始VEGF抑制剂的视觉结果相似，尽管从阿柏西普开始的眼睛具有更好的解剖学结果和更低的转换率。
